S. Kondo

发表

Brain Activity in Patients With Adductor Spasmodic Dysphonia Detected by Functional Magnetic Resonance Imaging.

A. Kiyuna, Norimoto Kise, Munehisa Hiratsuka, 2017, Journal of voice : official journal of the Voice Foundation.

Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients

H. Ueno, J. Furuse, M. Ikeda, 2012, Cancer Chemotherapy and Pharmacology.

Clinical impact of pentraxin family expression on prognosis of pancreatic carcinoma

H. Ueno, K. Tamura, T. Okusaka, 2013, British Journal of Cancer.

Glycemia control using A1C level in terminal cancer patients with preexisting type 2 diabetes.

S. Kondo, M. Kondo, Akira Kondo, 2013, Journal of palliative medicine.

Atezolizumab-induced Encephalitis in a Patient with Hepatocellular Carcinoma: A Case Report and Literature Review

H. Ueno, Masamichi Takahashi, T. Okusaka, 2022, Internal medicine.

Hypopharyngeal cancer risk in Japanese: Genetic polymorphisms related to the metabolism of alcohol- and tobacco-associated carcinogens

H. Hirakawa, A. Kiyuna, S. Kondo, 2019, Journal of cancer research and therapeutics.

Incidence and risk factors for venous thromboembolism in patients with pretreated advanced pancreatic carcinoma

H. Ueno, Mitsuhito Sasaki, T. Okusaka, 2018, Oncotarget.

Twenty-six cases of advanced ampullary adenocarcinoma treated with systemic chemotherapy.

H. Ueno, N. Hiraoka, M. Ikeda, 2014, Japanese journal of clinical oncology.

Spontaneous regression of hepatocellular carcinoma

H. Ueno, M. Ikeda, T. Okusaka, 2006, International Journal of Clinical Oncology.

Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.

H. Ueno, A. Hagihara, N. Hiraoka, 2010, Japanese journal of clinical oncology.

Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma

S. Kondo, Shiro Kimbara, S. Kimbara, 2016, World journal of gastroenterology.

Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer

H. Ueno, Hideaki Takahashi, Mitsuhito Sasaki, 2018, Investigational new drugs.

Transarterial infusion chemotherapy with cisplatin plus S-1 for hepatocellular carcinoma treatment: a phase I trial

H. Ueno, M. Ikeda, T. Okusaka, 2014, BMC Cancer.

Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer.

H. Ueno, M. Ikeda, T. Okusaka, 2015, Japanese journal of clinical oncology.

Raptor and rictor expression in patients with human papillomavirus-related oropharyngeal squamous cell carcinoma

H. Hirakawa, A. Kiyuna, S. Kondo, 2020, BMC cancer.

High-risk type human papillomavirus infection and p16 expression in laryngeal cancer

H. Hirakawa, A. Kiyuna, S. Kondo, 2019, Infectious Agents and Cancer.

Staging and prognosis of oropharyngeal carcinoma according to the 8th Edition of the American Joint Committee on Cancer Staging Manual in human papillomavirus infection

H. Hirakawa, A. Kiyuna, S. Kondo, 2018, European Archives of Oto-Rhino-Laryngology.

The influence of UGT1A1 polymorphisms on modified FOLFIRINOX dose in double-variant-type patients with advanced pancreatic cancer

H. Ueno, T. Okusaka, S. Hijioka, 2022, International Journal of Clinical Oncology.

Measurement of stapes footplate thickness in otosclerosis by ultra-high-resolution computed tomography

H. Hirakawa, T. Yamashiro, S. Kondo, 2020, Acta oto-laryngologica.

Efficacy of radiotherapy for primary tumor in patients with unresectable pancreatic neuroendocrine tumors

H. Ueno, J. Itami, Mitsuhito Sasaki, 2017, Japanese journal of clinical oncology.

Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization

H. Ueno, Y. Arai, Hideaki Takahashi, 2014, Journal of Gastroenterology.

Treatment Efficacy/Safety and Prognostic Factors in Patients with Advanced Biliary Tract Cancer Receiving Gemcitabine Monotherapy: An Analysis of 100 Cases

H. Ueno, J. Furuse, A. Hagihara, 2010, Oncology.

Phase I Study of Tremelimumab Monotherapy or in Combination With Durvalumab in Japanese Patients With Advanced Solid Tumors or Malignant Mesothelioma.

M. Okada, T. Nakano, S. Kondo, 2022, The oncologist.

Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis

H. Ueno, J. Itami, T. Okusaka, 2012, BMC Cancer.

Successful control of intractable hypoglycemia using radiopharmaceutical therapy with strontium-89 in a case with malignant insulinoma and bone metastases.

H. Ueno, A. Hagihara, J. Itami, 2012, Japanese journal of clinical oncology.

Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study

M. Kudo, J. Furuse, Y. Inaba, 2021, Journal of Gastroenterology.

Lipid profiling of pre-treatment plasma reveals biomarker candidates associated with response rates and hand–foot skin reactions in sorafenib-treated patients

Kosuke Saito, Yoshiro Saito, M. Ikeda, 2018, Cancer Chemotherapy and Pharmacology.

A case of pathological complete response after combination chemotherapy by sorafenib and cisplatin hepatic arterial infusion for an advanced hepatocellular carcinoma

H. Ojima, T. Okusaka, S. Nara, 2013 .

A phase II study of FOLFIRINOX with primary prophylactic pegfilgrastim for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer

H. Ueno, Shin Namiki, Mitsuhito Sasaki, 2021, International Journal of Clinical Oncology.

Assessment of adverse events via a telephone consultation service for cancer patients receiving ambulatory chemotherapy

K. Tamura, Satoshi Shiba, S. Kondo, 2015, BMC Research Notes.

Pancreatic neuroendocrine tumors: A single-center 20-year experience with 100 patients.

H. Ueno, Tesshi Yamada, N. Hiraoka, 2016, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

Cytotoxic chemotherapy for pancreatic neuroendocrine tumors

H. Ueno, Hideaki Takahashi, M. Ikeda, 2015, Journal of hepato-biliary-pancreatic sciences.

Long-term efficacy of tonsillectomy as a treatment for IgA nephropathy

A. Kiyuna, Norimoto Kise, S. Kondo, 2018 .

Circulating endothelial cells and other angiogenesis factors in pancreatic carcinoma patients receiving gemcitabine chemotherapy

H. Ueno, K. Tamura, T. Okusaka, 2012, BMC Cancer.

Chemotherapy for advanced poorly differentiated pancreatic neuroendocrine carcinoma

H. Ueno, Hideaki Takahashi, M. Ikeda, 2015, Journal of hepato-biliary-pancreatic sciences.

Cytogenetic confirmation of a gastrointestinal stromal tumor and ewing sarcoma/primitive neuroectodermal tumor in a single patient.

U. Tateishi, T. Hasegawa, S. Kondo, 2005, Japanese journal of clinical oncology.

Detection of human papillomavirus in branchial cleft cysts

H. Hirakawa, A. Kiyuna, S. Kondo, 2018, Oncology letters.

First‐in‐human study of the cancer peptide vaccine TAS0313 in patients with advanced solid tumors

Toshio Shimizu, A. Shimomura, K. Yonemori, 2020, Cancer science.

The influence of UGT1A1 polymorphisms on modified FOLFIRINOX dose in double-variant-type patients with advanced pancreatic cancer

H. Ueno, T. Okusaka, S. Hijioka, 2022, International Journal of Clinical Oncology.

Induction Chemotherapy in Hypopharyngeal Cancer: Influence of DNA Repair Gene Polymorphisms

H. Hirakawa, A. Kiyuna, S. Kondo, 2020, AntiCancer Research.

Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma

H. Ueno, H. Arioka, K. Koike, 2014, Investigational New Drugs.

Suprameatal Cochlear Implantation in a CHARGE Patient With a Novel CHD7 Variant and KALLMANN Syndrome Phenotype: A Case Report.

T. Kaname, K. Yanagi, S. Kondo, 2017, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.

Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study.

J. Furuse, M. Ikeda, T. Okusaka, 2019, The lancet. Gastroenterology & hepatology.

Perspectives in Therapy for Pancreatic Neuroendocrine Carcinomas

H. Ueno, M. Ikeda, T. Okusaka, 2009 .

Complicated paraneoplastic neurological syndromes: a report of two patients with small cell or non-small cell lung cancer

I. Endo, T. Mitsui, Toshio Matsumoto, 2003, Clinical Neurology and Neurosurgery.

Tremelimumab-associated tumor regression following after initial progression: two case reports.

A. Shimomura, M. Kodaira, K. Tamura, 2016, Immunotherapy.

Impact of the Duration of Diabetes Mellitus on the Outcome of Metastatic Pancreatic Cancer Treated with Gemcitabine: A Retrospective Study

H. Ueno, Hideaki Takahashi, H. Imaoka, 2019, Internal medicine.

An Oncogenic ALK Fusion and an RRAS Mutation in KRAS Mutation-Negative Pancreatic Ductal Adenocarcinoma.

H. Ueno, T. Kohno, N. Hiraoka, 2017, The oncologist.

Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer.

A. Italiano, K. Yoh, M. Millward, 2021, Cancer treatment and research communications.

Population Pharmacokinetics of Gemcitabine and Its Metabolite in Japanese Cancer Patients

H. Ueno, Teruhiko Yoshida, N. Saijo, 2010, Clinical pharmacokinetics.

Proportion of unresectable pancreatic cancer specimens obtained by endoscopic ultrasound-guided tissue acquisition meeting the OncoGuide™ NCC Oncopanel System analysis suitability criteria: a single-arm, phase II clinical trial

H. Ueno, T. Okusaka, S. Hijioka, 2022, Journal of Gastroenterology.

Clinical characteristics of pancreatic and biliary tract cancers associated with Lynch syndrome

H. Ueno, N. Hiraoka, T. Okusaka, 2021, Journal of hepato-biliary-pancreatic sciences.

Do all patients in the phase I oncology trials need to be hospitalized? Domestic but outstanding issues for globalization of drug development in Japan

A. Shimomura, K. Tamura, N. Kobayashi, 2017, International Journal of Clinical Oncology.

Human papillomavirus infection and immunohistochemical expression of cell cycle proteins pRb, p53, and p16INK4a in sinonasal diseases

M. Hasegawa, S. Kondo, Takayuki Uehara, 2015, Infectious Agents and Cancer.

Human papillomavirus infection and immunohistochemical expression of cell

M. Hasegawa, S. Kondo, Takayuki Uehara, 2015 .

Multicenter cooperative case survey of hepatitis B virus reactivation by chemotherapeutic agents

M. Kudo, J. Furuse, M. Mizokami, 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors

Toshio Shimizu, K. Yonemori, T. Koyama, 2022, Investigational New Drugs.

ERCC1 C8092A polymorphism predicts fair survival outcome in Japanese patients with pharyngo-laryngeal squamous cell carcinoma

H. Hirakawa, S. Kondo, H. Maeda, 2019, European Archives of Oto-Rhino-Laryngology.

Practical consideration for successful sequential tumor biopsies in first-in-human trials

Toshio Shimizu, K. Yonemori, Makoto Nishino, 2022, Investigational New Drugs.

Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label study

T. Koyama, S. Kondo, S. Iwasa, 2022, International Journal of Clinical Oncology.

M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in Asian patients with pretreated recurrent or refractory gastric cancer: Preliminary results from a phase I trial.

Y. Bang, Yoon-Koo Kang, K. Muro, 2018 .

Ocular toxicity of investigational anti-cancer drugs in early phase clinical trials

K. Yonemori, T. Koyama, Shigenobu Suzuki, 2022, Investigational New Drugs.

Safety and efficacy of S-IROX (S-1, irinotecan and oxaliplatin combination therapy) in patients with advanced pancreatic cancer: A multicenter phase 1b dose-escalation and dose-expansion clinical trial.

H. Ueno, J. Furuse, N. Sasahira, 2022, European journal of cancer.

Management of Local and Distant Recurrence after Pancreatic Cancer Resection

H. Ueno, Hideaki Takahashi, M. Ikeda, 2015 .

A prospective multicenter phase II study of FOLFIRINOX as a first-line treatment for patients with advanced and recurrent biliary tract cancer

K. Koike, Y. Morine, Kazuo Watanabe, 2022, Investigational New Drugs.

First‐in‐human study of ONO‐4578, an antagonist of prostaglandin E2 receptor 4, alone and with nivolumab in solid tumors

A. Shimomura, K. Yonemori, K. Tamura, 2022, Cancer science.

Transcatheter arterial infusion chemotherapy with a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma refractory to transcatheter arterial chemoembolization.

H. Ueno, A. Hagihara, Y. Arai, 2011, Japanese journal of clinical oncology.

Comparison of Chemotherapeutic Treatment Outcomes of Advanced Extrapulmonary Neuroendocrine Carcinomas and Advanced Small-Cell Lung Carcinoma

H. Ueno, Y. Shimada, N. Hiraoka, 2012, Neuroendocrinology.

First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors

E. Calleja, A. Shimomura, U. Banerji, 2019, Molecular Cancer Therapeutics.

First‐in‐human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors

Toshio Shimizu, A. Shimomura, K. Yonemori, 2019, Cancer science.

Progressive macrothrombocytopenia and hearing loss in a large family with DIAPH1 related disease

T. Kaname, K. Yanagi, Y. Chinen, 2017, American journal of medical genetics. Part A.

Brm transactivates the telomerase reverse transcriptase (TERT) gene and modulates the splicing patterns of its transcripts in concert with p54(nrb).

Shuji Fujita, Taiji Ito, T. Mizutani, 2008, The Biochemical journal.

Squamous Cell Carcinoma Antigen as a Diagnostic Marker of Nasal Inverted Papilloma

M. Hasegawa, A. Kiyuna, S. Kondo, 2016, American Journal of Rhinology & Allergy.

Impact of the Integrin Signaling Adaptor Protein NEDD9 on Prognosis and Metastatic Behavior of Human Lung Cancer

S. Iwata, C. Morimoto, M. Sakamoto, 2012, Clinical Cancer Research.

SHP-2 inhibits tyrosine phosphorylation of Cas-L and regulates cell migration.

S. Iwata, C. Morimoto, N. Dang, 2009, Biochemical and biophysical research communications.

Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer

V. Wacheck, M. Tajimi, S. Kondo, 2020, Investigational New Drugs.

Trends in the development of MET inhibitors for hepatocellular carcinoma.

S. Kondo, H. Okuma, 2016, Future oncology.

Clinical Development of Immune Checkpoint Inhibitors

S. Kondo, S. Kitano, K. Tada, 2015, BioMed research international.

Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma

H. Ueno, H. Tsuda, K. Tamura, 2013, International Journal of Clinical Oncology.

Two Cases of Anisakis Allergy

T. Enomoto, S. Kondo, Mikio Suzuki, 2014 .

Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor

T. Nishida, M. Imamura, K. Hara, 2013, Investigational New Drugs.

Construction and Validation of a Prognostic Index for Patients With Metastatic Pancreatic Adenocarcinoma

H. Ueno, S. Morita, M. Ikeda, 2011, Pancreas.

Phase I/II study of streptozocin monotherapy in Japanese patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors

M. Makuuchi, H. Ueno, K. Hasegawa, 2022, Japanese journal of clinical oncology.

The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study

Toshio Shimizu, A. Shimomura, K. Yonemori, 2021, Japanese journal of clinical oncology.

A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumors

Toshio Shimizu, M. Ono, K. Yonemori, 2021, Investigational New Drugs.

Phase I studies of peptide vaccine cocktails derived from GPC3, WDRPUH and NEIL3 for advanced hepatocellular carcinoma.

H. Ueno, J. Furuse, M. Ikeda, 2021, Immunotherapy.

Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies

Toshio Shimizu, A. Shimomura, T. Koyama, 2020, Cancer Chemotherapy and Pharmacology.

Model Informed Dosing Regimen and Phase I Results of the Anti‐PD‐1 Antibody Budigalimab (ABBV‐181)

A. Tolcher, A. Italiano, M. Tanner, 2020, Clinical and translational science.

Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer

M. Kudo, M. Osada, M. Ikeda, 2020, Journal for immunotherapy of cancer.

Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer

H. Ueno, T. Kohno, T. Shibata, 2017, Pancreas.

C-Reactive Protein Level Is an Indicator of the Aggressiveness of Advanced Pancreatic Cancer

H. Ueno, A. Ochiai, Hideaki Takahashi, 2016, Pancreas.

Chemoradiotherapy versus gemcitabine-based chemotherapy in patients with unresectable, locally advanced pancreatic cancer.

H. Ueno, A. Hagihara, T. Okusaka, 2010 .

Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer

H. Ueno, Hideaki Takahashi, M. Ikeda, 2017, Cancer Chemotherapy and Pharmacology.

First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer

W. Mason, D. Melisi, S. Estrem, 2021, Clinical Cancer Research.

First-In-Human Phase I Study of a Next-Generation, Oral, TGF b Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer

W. Mason, D. Melisi, S. Estrem, 2021 .

Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan

M. Miyazaki, J. Furuse, M. Nagino, 2010, British Journal of Cancer.

Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation‐positive advanced cutaneous melanoma

N. Yamazaki, A. Tsutsumida, Y. Kiyohara, 2018, The Journal of dermatology.

Evaluating Clinical Genome Sequence Analysis by Watson for Genomics

Laxmi Parida, Shunsuke Kondo, Hitoshi Ichikawa, 2018, Front. Med..

Impact of Hepatitis Virus on the Feasibility and Efficacy of Anticancer Agents in Patients With Hepatocellular Carcinoma in Phase I Clinical Trials

Toshio Shimizu, T. Okusaka, T. Koyama, 2019, Front. Oncol..

Coordinated Expression of HPV-6 Genes with Predominant E4 and E5 Expression in Laryngeal Papilloma

A. Murakami, H. Hirakawa, A. Kiyuna, 2021, Microorganisms.

Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours

Toshio Shimizu, A. Shimomura, K. Yonemori, 2019, Investigational New Drugs.

Germline mutations in cancer-predisposition genes in patients with biliary tract cancer

S. Yachida, S. Kaneko, Hideaki Takahashi, 2019, Oncotarget.

Phase 1 Trial of Wilms Tumor 1 (WT1) Peptide Vaccine and Gemcitabine Combination Therapy in Patients With Advanced Pancreatic or Biliary Tract Cancer

H. Ueno, M. Ikeda, Y. Heike, 2011, Journal of immunotherapy.

Long-term administration of Wilms tumor-1 peptide vaccine in combination with gemcitabine causes severe local skin inflammation at injection sites.

H. Ueno, M. Ikeda, Y. Heike, 2010, Japanese journal of clinical oncology.

Long-Term Administration of Wilms Tumor-1 Peptide Vaccine in Combination with Gemcitabine Causes Severe Local Skin Inﬂammation at Injection Sites

H. Ueno, M. Ikeda, Y. Heike, 2010 .

Do Recurrent and Metastatic Pancreatic Cancer Patients Have the Same Outcomes with Gemcitabine Treatment?

H. Ueno, A. Hagihara, M. Ikeda, 2009, Oncology.

Highly Sensitive Circulating MicroRNA Panel for Accurate Detection of Hepatocellular Carcinoma in Patients With Liver Disease

T. Ochiya, A. Tamori, H. Sakamoto, 2019, Hepatology communications.

Fine‐needle biopsy with 19G needle is effective in combination with endoscopic ultrasound‐guided tissue acquisition for genomic profiling of unresectable pancreatic cancer

H. Ueno, N. Hiraoka, K. Iwakiri, 2022, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society.

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia

M. Osada, K. Muro, Chia‐Chi Lin, 2021, Targeted Oncology.

Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer

Y. Bang, Yoon-Koo Kang, M. Osada, 2020, Clinical Cancer Research.

Hepatitis B Virus Reactivation during Treatment with Multi-Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma

H. Ueno, M. Ikeda, Satoshi Shiba, 2012, Case Reports in Oncology.

Transarterial (Chemo)Embolization for Liver Metastases in Patients with Neuroendocrine Tumors

H. Ueno, Y. Arai, Hideaki Takahashi, 2017, Oncology.

Diagnostic Ability of Endoscopic Ultrasound-Guided Tissue Acquisition Using 19-Gauge Fine-Needle Biopsy Needle for Abdominal Lesions

H. Ueno, Y. Ohe, T. Okusaka, 2023, Diagnostics.

Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma

H. Ueno, Y. Inaba, Yozo Sato, 2014, Cancer science.

Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study

K. Yonemori, H. Niu, T. Koyama, 2022, Cancer research communications.

Oral chemotherapy for the treatment of hepatocellular carcinoma

S. Kondo, S. Yamamoto, 2018, Expert opinion on pharmacotherapy.

Gemcitabine in Patients With Intraductal Papillary Mucinous Neoplasm With an Associated Invasive Carcinoma of the Pancreas

H. Ueno, N. Hiraoka, M. Ikeda, 2013, Pancreas.

Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis

H. Ueno, J. Itami, T. Okusaka, 2012, BMC Cancer.

Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: Final results of a multicenter phase II study

M. Kudo, Y. Inaba, A. Hagihara, 2023, Hepatology research : the official journal of the Japan Society of Hepatology.

769TiPRandomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group Study (JCOG1407)

H. Katayama, J. Furuse, M. Ikeda, 2017 .

Prognostic Factors for Survival in Patients with Advanced Intrahepatic Cholangiocarcinoma Treated with Gemcitabine plus Cisplatin as First-Line Treatment

H. Ueno, Mitsuhito Sasaki, T. Okusaka, 2017, Oncology.

Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial

M. Makuuchi, M. Kudo, K. Ueshima, 2014, Journal of Gastroenterology.

Novel endoscopic technique for tri-segment drainage in patients with unresectable hilar malignant biliary strictures (with video).

H. Ueno, Yutaka Saito, T. Okusaka, 2020, Gastrointestinal endoscopy.

Endoscopic ultrasound‐guided choledochoduodenostomy without fistula dilation using a stent with a 5.9‐Fr delivery system: Comparison to a conventional procedure with fistula dilation

H. Ueno, Yutaka Saito, T. Okusaka, 2021, DEN open.

Treatment outcome for systemic chemotherapy for recurrent pancreatic cancer after postoperative adjuvant chemotherapy.

H. Ueno, M. Ikeda, T. Okusaka, 2012, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

A phase I and pharmacokinetic study of taladegib, a Smoothened inhibitor, in Japanese patients with advanced solid tumors

H. Ueno, H. Murakami, M. Tajimi, 2018, Investigational New Drugs.

Comparison of 6-mm and 10-mm-diameter, fully-covered, self-expandable metallic stents for distal malignant biliary obstruction

H. Ueno, N. Enomoto, M. Sone, 2022, Endoscopy International Open.

Global trends in the distribution of cancer types among patients in oncology phase I trials, 1991–2015

Toshio Shimizu, T. Koyama, S. Kondo, 2018, Investigational new drugs.

Improved survival among patients enrolled in oncology phase 1 trials in recent decades

Toshio Shimizu, A. Shimomura, K. Yonemori, 2019, Cancer Chemotherapy and Pharmacology.

Genetic inhibition of CRMP2 phosphorylation at serine 522 promotes axonal regeneration after optic nerve injury

Y. Goshima, T. Araki, S. Kondo, 2019, Scientific Reports.

372PDFirst-in-human (FIH) study of TAS-120, a highly selective covalent oral fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors

K. Yoh, Hideaki Takahashi, H. Hirai, 2017 .

Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients

H. Ueno, N. Saijo, M. Ikeda, 2009, British Journal of Cancer.

Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer

A. Shimomura, K. Tamura, S. Kondo, 2016, Cancer Chemotherapy and Pharmacology.

Efficacy of endoscopic ultrasound-guided tissue acquisition for solid pancreatic lesions 20 mm or less in diameter suspected as neuroendocrine tumors or requiring differentiation

H. Ueno, N. Hiraoka, T. Okusaka, 2023, Journal of Gastroenterology.

High-risk type human papillomavirus infection and p16 expression in laryngeal cancer

H. Hirakawa, A. Kiyuna, S. Kondo, 2019, Infectious Agents and Cancer.

Germline variants in pancreatic cancer patients with a personal or family history of cancer fulfilling the revised Bethesda guidelines

H. Ueno, S. Yachida, T. Okusaka, 2018, Journal of Gastroenterology.

Human papillomavirus infection and immunohistochemical expression of cell cycle proteins pRb, p53, and p16INK4a in sinonasal diseases

M. Hasegawa, S. Kondo, Takayuki Uehara, 2015, Infectious Agents and Cancer.

Usefulness of a laser-cut covered metal stent with a 7F delivery sheath in endoscopic ultrasound-guided biliary drainage without fistula dilation

H. Ueno, T. Okusaka, S. Hijioka, 2022, Endoscopy International Open.

Gemcitabine-induced pleuropericardial effusion in a patient with pancreatic cancer.

H. Ueno, A. Hagihara, T. Okusaka, 2012, Japanese journal of clinical oncology.

A retrospective analysis of factors associated with selection of end-of-life care and actual place of death for patients with cancer

H. Ueno, T. Shimazu, T. Okusaka, 2014, BMJ Open.

M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in Asian patients with pretreated biliary tract cancer: Preliminary results from a phase I trial.

M. Osada, M. Ikeda, D. Oh, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Merestinib monotherapy or in combination for japanese patients with advanced and/or metastatic cancer: A phase 1 study

T. Koyama, S. Kondo, T. Doi, 2021, Cancer medicine.

Genetic inhibition of CRMP2 phosphorylation at serine 522 promotes axonal regeneration after optic nerve injury

Y. Goshima, T. Araki, S. Kondo, 2019, Scientific Reports.

Recent updates in the use of pharmacological therapies for downstaging in patients with hepatocellular carcinoma

S. Kondo, Y. Maruki, T. Takamoto, 2023, Expert opinion on pharmacotherapy.

MO10-6 Phase 1 study of retifanlimab (anti-PD-1) and INCB001158 (arginase inhibitor), alone or in combination, in solid tumors

Toshio Shimizu, K. Yonemori, K. Yoh, 2021, Annals of Oncology.

Quality evaluation of investigator‐initiated trials using post‐approval cancer drugs in Japan

S. Kondo, H. Hosoi, J. Hashimoto, 2017, Cancer science.

Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma

H. Ueno, H. Arioka, K. Koike, 2014, Investigational New Drugs.

Construction and Validation of a Prognostic Index for Patients With Metastatic Pancreatic Adenocarcinoma

H. Ueno, S. Morita, M. Ikeda, 2011, Pancreas.

Cytotoxic chemotherapy for pancreatic neuroendocrine tumors

H. Ueno, Hideaki Takahashi, M. Ikeda, 2015, Journal of hepato-biliary-pancreatic sciences.

Phase II trial of niraparib for BRCA-mutated biliary tract, pancreatic and other gastrointestinal cancers: NIR-B

D. Sakai, M. Ueno, S. Kondo, 2024, Future oncology.

Lipid profiling of pre-treatment plasma reveals biomarker candidates associated with response rates and hand–foot skin reactions in sorafenib-treated patients

Kosuke Saito, Yoshiro Saito, M. Ikeda, 2018, Cancer Chemotherapy and Pharmacology.

Chemotherapy for advanced poorly differentiated pancreatic neuroendocrine carcinoma

H. Ueno, Hideaki Takahashi, M. Ikeda, 2015, Journal of hepato-biliary-pancreatic sciences.

A multicenter, open-label, phase I study of nivolumab alone or in combination with gemcitabine plus cisplatin in patients with unresectable or recurrent biliary tract cancer.

J. Furuse, M. Ikeda, T. Okusaka, 2019, Journal of Clinical Oncology.

A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors

A. Shimomura, K. Yonemori, N. Hayata, 2022, Cancer Chemotherapy and Pharmacology.

Clinicopathological Findings and Treatment Outcomes of Patients with Primary Hepatobiliary Neuroendocrine Neoplasms: A Retrospective Single-institution Analysis

H. Ueno, N. Hiraoka, T. Okusaka, 2023, Internal medicine.

Phase I/II study of lenvatinib (E7080), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC): Phase I results.

H. Ueno, M. Ikeda, T. Okusaka, 2013 .